[Preclinical biomarker research and patient stratification of molecular target agents: the anti-angiogenic inhibitor Lenvatinib mesylate (E7080)]

MeSH terms

• Angiogenesis Inhibitors* / chemistry
• Angiogenesis Inhibitors* / pharmacology
• Angiogenesis Inhibitors* / therapeutic use
• Animals
• Biomarkers, Tumor*
• Disease Models, Animal
• Drug Evaluation, Preclinical
• Humans
• Melanoma / drug therapy
• Molecular Targeted Therapy*
• Mutation
• Neoplasms / blood supply*
• Neoplasms / drug therapy*
• Neoplasms / genetics
• PTEN Phosphohydrolase / genetics
• Phenylurea Compounds* / chemistry
• Phenylurea Compounds* / pharmacology
• Phenylurea Compounds* / therapeutic use
• Precision Medicine
• Proto-Oncogene Proteins B-raf / genetics
• Quinolines* / chemistry
• Quinolines* / pharmacology
• Quinolines* / therapeutic use
• Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
• Skin Neoplasms / drug therapy
• Translational Research, Biomedical / trends